SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced that it will share six abstracts, ...

According to the World Cancer Research Fund, more than 100,000 men are newly diagnosed with prostate cancer annually in Japan, and a portion of those patients will be diagnosed with or later progress ...

Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan's Ministry of Health ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Myriad Genetics (NASDAQ:MYGN) and the best ...

Too many patient access strategies stop at “script filled”. But this approach is ultimately short-sighted, failing to build ...

A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as investors reacted to escalating uncertainty tied to the U.S.

Explore Forbes' 121 best healthcare employers for culture, featuring top U.S. health systems, insurers, and pharma leaders ranked for workplace excellence.

Quest Diagnostics (NYSE:DGX) reported first-quarter 2026 results that management said reflected broad-based organic growth, ...

Paradigm Value's heady relative performance has trailed off a bit lately. As of ((UNHANDLED TYPE: NoneType for 'None')), the fund has assets totaling almost $50.85 million invested in 44 different ...

Partial responses in half of patients with platinum-resistant disease, as crowded ADC list ...